RBC Capital Maintains Outperform on Exelixis, Lowers Price Target to $31
RBC Capital analyst Kennen MacKay maintains Exelixis (NASDAQ:EXEL) with a Outperform and lowers the price target from $32 to $31.
HC Wainwright & Co. Maintains Buy on Exelixis, Lowers Price Target to $52
HC Wainwright & Co. analyst Michael King maintains Exelixis (NASDAQ:EXEL) with a Buy and lowers the price target from $65 to $52.
Exelixis Q3 EPS $0.20 Beats $0.16 Estimate, Sales $328.42M Miss $354.02M Estimate
Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.16 by 25 percent. This is a 400 percent increase over earnings of $0.04 per share from the same period
Exelixis: Q3 Earnings Insights
Exelixis (NASDAQ:EXEL) reported its Q3 earnings results on Tuesday, November 2, 2021 at 04:05 PM.
Here's what investors need to know about the announcement.
Exelixis Earnings Perspective: Return On Capital Employed
According to Benzinga Pro, during Q2, Exelixis (NASDAQ:EXEL) earned $123.01 million, a 2770.02% increase from the preceding quarter. Exelixis also posted a total of $385.18 million in sales, a 42.54% increase since Q1.
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell
• Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
